You are here

  • Home
  • Archive
  • Volume 17, Issue 5
  • Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis

Article metrics

Article menu

Download PDFPDF

Original Article
Pegfilgrastim for the prevention of febrile neutropenia in patients with epithelial ovarian carcinoma—a cost-effectiveness analysis

 

Online download statistics by month:

Online download statistics by month: March 2019 to April 2024

AbstractFullPdf
Mar 2019800
Apr 20192901
May 20191602
Jun 20192701
Jul 20191801
Aug 20191200
Sep 20191602
Oct 20192300
Nov 2019200
Dec 20192000
Jan 20201800
Feb 20201600
Mar 2020700
Apr 2020801
May 20202000
Jun 20201601
Jul 20201801
Aug 2020801
Sep 20201000
Oct 20201200
Nov 20203102
Dec 20201000
Jan 20212001
Feb 2021400
Mar 20211201
Apr 20211401
May 20211004
Jun 2021101
Jul 2021102
Aug 2021101
Oct 20212401
Nov 2021601
Dec 20211200
Jan 20221601
Feb 20221801
Mar 20221000
Apr 20221500
May 20223901
Jun 20225802
Jul 20222600
Aug 20223600
Sep 20224001
Oct 20225801
Nov 20221400
Dec 20221300
Jan 20231501
Feb 20235000
Mar 20232301
Apr 2023801
May 2023200
Jun 20231601
Jul 2023900
Aug 2023600
Sep 20231000
Oct 2023600
Nov 20231200
Dec 20231800
Jan 2024800
Feb 20241000
Mar 2024800
Apr 20241400
Total1008037